Advertising campaign by US law firms: Thousands of new glyphosate lawsuits against Bayer

The legal pressure on Bayer for possible cancer risks of the weed killer glyphosate is increasing. In the United States, the number of plaintiffs skyrocketed - also because the law firms specializing in such lawsuits recently raised their TV advertising significantly.

By mid-October, the company had received complaints from around 42,700 plaintiffs, Bayer said. That's a lot more than in July when it was around 18,400.

The group said that he would continue "decided to defend". However, the next negotiations are not until January. The head of the agribusiness, Executive Board member Liam Condon, recently appeared confident in settling the "sooner or later" dispute over the weed killer. The pressure on Bayer to reach an agreement is likely to increase as the number of plaintiffs grows.

more on the subject

Chief of the EU Food Authority "We had too lax rules for glyphosate"

The last three glyphosate processes in the US were all postponed. Mediator Ken Feinberg is trying to reach an out-of-court settlement between Bayer and US plaintiffs. According to his own statement, Bayer wants to contribute "constructively" to the mediation process.

So far, the group has lost three lawsuits in the first instance in the US and was sentenced by the jury to high damages. The company has consistently rejected the allegations, pointing out that regulatory agencies worldwide consider the herbicide glyphosate safe when used properly.

The lawsuit Bayer has brought with the billion dollar takeover of the US seed manufacturer Monsanto in the house, which has developed glyphosate. The acquisition significantly expanded the agricultural business and made Bayer the world's largest supplier of seeds and crop protection products.

more on the subject

Bayer's Monsanto takeover stations of decline

While the lawsuit lurks on Bayer, the daily business runs better than expected thanks to the demand for agricultural products and medicines.

Overall, Bayer came in the third quarter on an adjusted result of 2.29 billion euros, an increase of 7.5 percent. Consolidated net profit fell by almost 64 percent to 1.04 billion euros, but in the previous year the company posted high special income. Sales increased by around six percent to 9.83 billion.

The share price of Bayer rose in the morning by more than two percent.